Ph2 INBRX-109 (Unresectable or Metastatic Conventional Chondrosarcoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called INBRX-109 (the study drug) is a safe and effective option for people with unresectable or metastatic conventional chondrosarcoma.

What is the Condition Being Studied?

Unresectable or Metastatic Conventional Chondrosarcoma

Who Can Participate in the Study?

Adults ages 18+ who are diagnosed with unresectable or metastatic conventional chondrosarcoma.

For more information on who can participate in this study, please contact the study team at stephanie.weaver@duke.edu.

Age Group

Adults

What is Involved?

If you choose to join this study, during the screening period you will:

Have a tumor biopsy (unless a previous tumor tissue sample is available)
Have blood draws
Have imaging scans (CT or MRI)
Have an electrocardiogram (ECG) to check your heart function

If you are eligible for the study drug period, you will:

Get a random assignment to receive either the study drug or placebo (inactive substance) by intravenous (IV) infusion

Take a dose of 600-1200 mg of N-acetylcysteine and get a prescription for 8 mg dexamethasone

Have clinical visits for full physical examination and procedures including urine and blood sample collection

Have imaging scans (CT and MRI)

Have phone calls with the study team

Study Details

Full Title

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Principal Investigator

Juneko Grilley-Olson, MD

Medical Oncologist

Protocol Number

IRB: PRO00108836

NCT: NCT04950075

Phase

Phase II

ClinicalTrials.gov

View on ClinicalTrials.gov

Enrollment Status

Open for Enrollment

Contact the Duke Recruitment Innovation Center

MyResearchPartners@duke.edu

919-681-5698